Differentiation of human embryonic stem cells
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C12N-005/00
C12N-005/02
C12N-005/071
출원번호
US-0105285
(2011-05-11)
등록번호
US-9752125
(2017-09-05)
발명자
/ 주소
Xu, Jean
출원인 / 주소
Janssen Biotech, Inc.
대리인 / 주소
Gianneschi, Lois A.
인용정보
피인용 횟수 :
0인용 특허 :
75
초록▼
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein greater
The present invention provides methods to promote the differentiation of pluripotent stem cells into insulin producing cells. In particular, the present invention provides a method to produce a population of cells expressing markers characteristic of the pancreatic endoderm lineage, wherein greater than 50% of the cells in the population co-express PDX1 and NKX6.1.
대표청구항▼
1. A cell culture comprising: a medium supplemented with ALK5 inhibitor II and a protein kinase C activator;human definitive endoderm cells; anda population of human cells expressing markers characteristic of the pancreatic endoderm lineage,wherein the presence of ALK5 inhibitor II and the protein k
1. A cell culture comprising: a medium supplemented with ALK5 inhibitor II and a protein kinase C activator;human definitive endoderm cells; anda population of human cells expressing markers characteristic of the pancreatic endoderm lineage,wherein the presence of ALK5 inhibitor II and the protein kinase C activator in the culture increases the percentage of pancreatic endoderm cells that co-express PDX1 and NKX6.1, and results in a culture wherein greater than 60% of the cells in the population are pancreatic endoderm cells co-expressing PDX1 and NKX6.1,wherein the human definitive endoderm cells are derived from established lines of human pluripotent cells, andwherein cells in the isolated PDX1 and NKX6.1 co-expressing population express CDX2. 2. The cell culture of claim 1 wherein greater than 70% of the cells in the population co-express PDX1 and NKX6.1. 3. The cell culture of claim 1 wherein greater than 80% of the cells in the population co-express PDX1 and NKX6.1. 4. The cell culture of claim 1 wherein greater than 90% of the cells in the population co-express PDX1 and NKX6.1. 5. The cell culture of claim 1, wherein cells in the cell population express ISL1 and/or NEUROD1. 6. The cell culture of claim 1, wherein the protein kinase C activator is selected from the group consisting of (2S, 5S)-(E, E)-8-(5-(4-(Trifluoromethyl)phenyl)-2,4-pentadiemoylamino) benzolactam (TPB), phorbol-12-myristate-13-acetate (PMA), and phorbol-12,13-dibutyrate (PDBu). 7. A cell culture comprising: a medium supplemented with ALK5 inhibitor II and a protein kinase C activator;human definitive endoderm cells; anda population of human cells expressing markers characteristic of the pancreatic endoderm lineage,wherein the presence of ALK5 inhibitor II and the protein kinase C activator in the culture increases the percentage of pancreatic endoderm cells that co-express PDX1 and NKX6.1, and results in a culture wherein greater than 60% of the cells in the population are pancreatic endoderm cells co-expressing PDX1 and NKX6.1,wherein the human definitive endoderm cells are derived from established lines of human pluripotent cells, andwherein the PDX1 and NKX6.1 co-expressing cells in the isolated population differentiate into insulin secreting cells in vivo. 8. The cell culture of claim 7, wherein cells in the cell population express ISL1 and/or NEUROD1. 9. The cell culture of claim 7, wherein greater than 70% of the cells in the population co-express PDX1 and NKX6.1. 10. The cell culture of claim 7, wherein greater than 80% of the cells in the population co-express PDX1 and NKX6.1. 11. The cell culture of claim 7, wherein greater than 90% of the cells in the population co-express PDX1 and NKX6.1. 12. The cell culture of claim 7, wherein the protein kinase C activator is selected from the group consisting of (2S, 5S)-(E, E)-8-(5-(4-(Trifluoromethyl)phenyl)-2,4-pentadiemoylamino) benzolactam (TPB), phorbol-12-myristate-13-acetate (PMA), and phorbol-12,13-dibutyrate (PDBu). 13. The cell culture of claim 1, wherein the cells expressing markers characteristic of the pancreatic endoderm lineage are pancreatic endoderm cells. 14. The cell culture of claim 7, wherein the cells expressing markers characteristic of the pancreatic endoderm lineage are pancreatic endoderm cells. 15. A cell culture comprising: a medium supplemented with ALK5 inhibitor II and a protein kinase C activator;human definitive endoderm cells; anda population comprising pancreatic endoderm cells,wherein the presence of ALK5 inhibitor II and the protein kinase C activator in the culture increases the percentage of pancreatic endoderm cells that co-express PDX1 and NKX6.1, and results in a culture wherein greater than 90% of the cells in the population are pancreatic endoderm cells co-expressing PDX1 and NKX6.1, andwherein the human definitive endoderm cells are derived from established lines of human pluripotent cells. 16. The cell culture of claim 1, wherein cells in the cell population express NEUROD1. 17. The cell culture of claim 1, wherein the cells are obtained by culturing a population of cells expressing markers characteristic of the definitive endoderm lineage in a medium supplemented with a protein kinase C activator and lacking FGF10. 18. The cell culture of claim 7, wherein cells in the cell population express NEUROD1. 19. The cell culture of claim 1, wherein the cells are obtainable by culturing a population of cells expressing markers characteristic of the definitive endoderm lineage in a medium supplemented with a protein kinase C activator and lacking FGF10. 20. A cell culture comprising: a medium supplemented with (2S, 5S)-(E, E)-8-(5-(4-(Trifluoromethyl)phenyl)-2,4-pentadiemoylamino) benzolactam (TPB);human definitive endoderm cells; anda population of human cells expressing markers characteristic of the pancreatic endoderm lineage,wherein the presence of TPB in the culture increases the percentage of pancreatic endoderm cells that co-express PDX1 and NKX6.1, and results in a culture wherein greater than 60% of the cells in the population are pancreatic endoderm cells co-expressing PDX1 and NKX6.1,wherein the human definitive endoderm cells are derived from established lines of human pluripotent cells, andwherein cells in the isolated population express CDX2. 21. The cell culture of claim 1, wherein the culturing of the first population of cells expressing markers characteristic of the definitive endoderm does not require purification. 22. The cell culture of claim 7, wherein the culturing of the first population of cells expressing markers characteristic of the definitive endoderm does not require purification. 23. The cell culture of claim 15, wherein the culturing of the first population of cells expressing markers characteristic of the definitive endoderm does not require purification. 24. The cell culture of claim 20, wherein the culturing of the first population of cells expressing markers characteristic of the definitive endoderm does not require purification.
Yi, Chin-Feng; Gosiewska, Anna; Roweton, Susan, Bioabsorbable bag containing bioabsorbable materials of different bioabsorption rates for tissue engineering.
Coon Hayden G. ; Ambesi-Impiombato Francesco Saverio,ITX ; Curcio Francesco,ITX, Cell cultures of and cell culturing method for nontransformed pancreatic, thyroid, and parathyroid cells.
Chatelier Ronald C. (9 Apple Gve Bayswater ; Victoria 3168 AUX) Griesser Hans J. (20 View Road The Patch ; Victoria 3792 AUX) Steele John G. (7 The Carriageway North Rocks ; NSW 2151 AUX) Johnson Gra, Cell growth substrates.
Melton, Douglas A.; Borowiak, Malgorzata; Maehr, Rene; Chen, Shuibing; Tang, Weiping; Fox, Julia L.; Schreiber, Stuart L., Compositions and methods for promoting the generation of definitive endoderm.
Vyakarnam Murty N. ; Zimmerman Mark C. ; Scopelianos Angelo George ; Chun Iksoo ; Melican Mora C. ; Bazilio Clairene A. ; Roller Mark B. ; Gorky David V., Foam composite for the repair or regeneration of tissue.
Vacanti Joseph P. (Winchester MA) Freeman Michael R. (Boston MA), Genitourinary cell-matrix structure for implantation into a human and a method of making.
Evans Ronald M. (San Diego CA) Rosenfeld Michael G. (San Diego CA) Cerelli Gail (Cardiff CA) Mayo Kelly E. (Wilmette IL) Spiess Joachim (Encinitas CA) Rivier Jean E. F. (La Jolla CA) Vale ; Jr. Wylie, Human inhibin.
McIntosh Kevin R. ; Mosca Joseph D. ; Klyushnenkova Elena N., Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
Bryhan, Marie D.; Gagnon, Paul E.; LaChance, Oliva V.; Shen, Zhong-he; Wang, Hongming, Method for creating a cell growth surface on a polymeric substrate.
Bodnar, Andrea G.; Chiu, Choy-Pik; Gold, Joseph D.; Inokuma, Margaret; Murai, James T.; West, Michael D., Methods and materials for the growth of primate-derived primordial stem cells in feeder-free culture.
Dalton, Stephen; Sheppard, Allan; Jones, Karen; Baetge, E. Edward; D'Amour, Kevin A.; Agulnick, Alan D., Methods for increasing definitive endoderm differentiation of pluripotent human embryonic stem cells with PI-3 kinase inhibitors.
Mason Anthony J. (San Francisco CA) Seeburg Peter H. (Heidelberg DEX), Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic aci.
Mason Anthony J. ; Seeburg Peter H., Nucleic acid encoding the mature .beta..sub.B chain of inhibin and method for synthesizing polypeptides using such nucl.
Mason Anthony J. (San Francisco CA) Seeburg Peter H. (San Francisco CA), Nucleic acid encoding the mature a
상세보기
Mason Anthony J. (San Francisco CA) Seeburg Peter H. (San Francisco CA), Nucleic acid encoding the mature bAchain of inhibin and method for synthesizing.
Vyakarnam Murty N. ; Zimmerman Mark C. ; Scopelianos Angelo George ; Roller Mark B. ; Gorky David V., Porous tissue scaffoldings for the repair of regeneration of tissue.
Murty N. Vyakarnam ; Mark C. Zimmerman ; Angelo George Scopelianos ; Mark B. Roller ; David V. Gorky, Porous tissue scaffoldings for the repair or regeneration of tissue.
Vyakarnam, Murty N.; Zimmerman, Mark C.; Scopelianos, Angelo George; Roller, Mark B.; Gorky, David V., Porous tissue scaffoldings for the repair or regeneration of tissue.
MacMichael Donald Bruce Atherton,GBX ; Drake David,GBX ; Arlington Stephen Adrian,GBX ; Normansell Ian David,GBX ; Addicott John Kenneth,GBX ; Divers Moira Sloan,GBX ; Stovold John Spencer,GBX, Process and apparatus for cell sorting.
Melican, Mora Carolynne; Li, Yufu; Brown, Kelly R.; Chun, Iksoo; McAllen, III, John; Rezania, Alireza; Scopelianos, Angelo G.; Vyakarnam, Murty N., Reinforced tissue implants and methods of manufacture and use.
Mistry,Sanjay; Messina,Darin J.; Harris,Ian Ross; Harmon,Alexander M.; Seyda,Agnieszka; Yi,Chin Feng; Gosiewska,Anna, Treatment of retinitis pigmentosa with human umbilical cord cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.